FDA Approves New Treatment for Pediatric APDS Patients

The FDA has approved leniolisib (Joenja) for children aged 4-11 with Activated PI3Kδ Syndrome (APDS) weighing at least 27 kg. This marks the first specific treatment for this pediatric age group, addressing the underlying disease pathway. The approval provides a new therapeutic option where previous management was limited to symptom control.